Regeneron enters neurology with FDA approval of Livsayis for myasthenia gravis on November 19, 2026 Alnylam Approved C5 level cemdisiran Livsayis Myasthenia Gravis, Generalized Regeneron RNA, Small Interfering United States Food and Drug Administration +